These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 29695598

  • 1. Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Gerardi C, Bertele' V, Rossi S, Garattini S, Banzi R.
    Neurology; 2018 May 22; 90(21):964-973. PubMed ID: 29695598
    [Abstract] [Full Text] [Related]

  • 2. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C, Aloi JJ.
    Clin Ther; 2015 Apr 01; 37(4):691-715. PubMed ID: 25846320
    [Abstract] [Full Text] [Related]

  • 3. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 4. Teriflunomide for multiple sclerosis.
    He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.
    Cochrane Database Syst Rev; 2016 Mar 22; 3(3):CD009882. PubMed ID: 27003123
    [Abstract] [Full Text] [Related]

  • 5. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R, Harel A, Lublin F.
    Annu Rev Med; 2016 Mar 22; 67():309-21. PubMed ID: 26394285
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA, Kamal KM, Pawar G.
    J Manag Care Spec Pharm; 2017 Jun 22; 23(6):666-676. PubMed ID: 28530523
    [Abstract] [Full Text] [Related]

  • 7. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL, Tyor WR.
    J Investig Med; 2017 Jun 22; 65(5):883-891. PubMed ID: 28130412
    [Abstract] [Full Text] [Related]

  • 8. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C.
    CNS Drugs; 2021 Mar 22; 35(3):317-330. PubMed ID: 33743151
    [Abstract] [Full Text] [Related]

  • 9. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
    Kretzschmar B, Pellkofer H, Weber MS.
    Curr Neurol Neurosci Rep; 2016 Apr 22; 16(4):38. PubMed ID: 26944956
    [Abstract] [Full Text] [Related]

  • 10. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P, Martinelli V, Pfleger C, Rieckmann P, Alonso-Magdalena L, Galazka A, Dangond F, Phillips L.
    Clin Ther; 2019 Feb 22; 41(2):249-260.e18. PubMed ID: 30846120
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.
    Curr Med Res Opin; 2014 Apr 22; 30(4):613-27. PubMed ID: 24195574
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D, Nicholas J, Carraro M, Zhou J, Hou Q, Babb J, Riester K, Mendoza JP, Livingston T, Jhaveri M.
    Mult Scler Relat Disord; 2019 Jan 22; 27():101-111. PubMed ID: 30368221
    [Abstract] [Full Text] [Related]

  • 13. Induction and escalation therapies in multiple sclerosis.
    Fenu G, Lorefice L, Frau F, Coghe GC, Marrosu MG, Cocco E.
    Antiinflamm Antiallergy Agents Med Chem; 2015 Jan 22; 14(1):26-34. PubMed ID: 25938688
    [Abstract] [Full Text] [Related]

  • 14. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
    Rommer PS, Zettl UK.
    Expert Opin Pharmacother; 2018 Apr 22; 19(5):483-498. PubMed ID: 29528247
    [Abstract] [Full Text] [Related]

  • 15. Effector and regulatory B cells in Multiple Sclerosis.
    Staun-Ram E, Miller A.
    Clin Immunol; 2017 Nov 22; 184():11-25. PubMed ID: 28461106
    [Abstract] [Full Text] [Related]

  • 16. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R, González-Caballero JL, Espinosa-Rosso R, Gómez-Gómez C.
    Sci Rep; 2021 Jun 15; 11(1):12533. PubMed ID: 34131191
    [Abstract] [Full Text] [Related]

  • 17. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, Pascale A.
    Pharmacol Res; 2017 Jun 15; 120():279-293. PubMed ID: 28396093
    [Abstract] [Full Text] [Related]

  • 18. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J, Taylor BV, Blizzard L, Simpson S, Palmer AJ, van der Mei IAF.
    J Neurol Neurosurg Psychiatry; 2018 Nov 15; 89(11):1200-1207. PubMed ID: 29921609
    [Abstract] [Full Text] [Related]

  • 19. Teriflunomide for multiple sclerosis.
    He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD009882. PubMed ID: 23235682
    [Abstract] [Full Text] [Related]

  • 20. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH, Wakefield RA.
    Am J Health Syst Pharm; 2015 Jan 01; 72(1):25-38. PubMed ID: 25511835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.